Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Follow-Up Questions
¿Cuál es el ratio P/E de Jazz Pharmaceuticals PLC (JAZZ)?
El ratio P/E de Jazz Pharmaceuticals PLC es 14.3465
¿Quién es el CEO de Jazz Pharmaceuticals PLC?
Ms. Renee Gala es el President de Jazz Pharmaceuticals PLC, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción JAZZ?
El precio actual de JAZZ es de $138.53, ha increased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Jazz Pharmaceuticals PLC?
Jazz Pharmaceuticals PLC pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Jazz Pharmaceuticals PLC?
La capitalización bursátil actual de Jazz Pharmaceuticals PLC es $8.4B
¿Es Jazz Pharmaceuticals PLC una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 20 analistas han realizado calificaciones de análisis para Jazz Pharmaceuticals PLC, incluyendo 8 fuerte compra, 15 compra, 2 mantener, 0 venta, y 8 fuerte venta